ESPR Stock Forecast 2025-2026
Distance to ESPR Price Targets
ESPR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Esperion (ESPR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ESPR and similar high-potential opportunities.
Latest ESPR Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, ESPR has a bullish consensus with a median price target of $5.00 (ranging from $2.05 to $16.00). The overall analyst rating is Buy (7.8/10). Currently trading at $0.95, the median forecast implies a 426.3% upside. This outlook is supported by 6 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 1,584.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESPR Analyst Ratings
ESPR Price Target Range
Latest ESPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Mar 5, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $4.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Feb 11, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $4.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 23, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $7.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $0.00 |
| Dec 18, 2024 | Goldman Sachs | Paul Choi | Neutral | Reinstates | $4.00 |
| Dec 17, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $8.00 |
| Dec 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $6.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $16.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
Esperion Therapeutics Inc. (ESPR) Competitors
The following stocks are similar to Esperion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Esperion Therapeutics Inc. (ESPR) Financial Data
Esperion Therapeutics Inc. has a market capitalization of $187.96M with a P/E ratio of -3.4x. The company generates $332.31M in trailing twelve-month revenue with a -15.6% profit margin.
Revenue growth is +114.3% quarter-over-quarter, while maintaining an operating margin of -6.4% and return on equity of +13.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Esperion Therapeutics Inc. (ESPR) Business Model
About Esperion Therapeutics Inc.
Develops innovative lipid-lowering therapies.
Esperion Therapeutics generates revenue by developing and commercializing oral medications for cholesterol management, specifically targeting patients with cardiovascular disease who cannot achieve desired cholesterol levels with existing treatments. The company's lead product, a non-statin therapy, offers an alternative for statin-intolerant patients, thereby expanding the market for lipid-lowering therapies.
Based in Ann Arbor, Michigan, the company focuses on improving patient compliance and outcomes through convenient dosing schedules. Esperion engages with healthcare professionals to align its offerings with advancements in medical research and treatment protocols, positioning itself as a significant player in the cardiovascular pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
304
CEO
Mr. Sheldon L. Koenig
Country
United States
IPO Year
2013
Website
www.esperion.comEsperion Therapeutics Inc. (ESPR) Latest News & Analysis
Research on ATP Citrate Lyase (ACLY) reveals new insights into its biology and potential therapeutic applications for various life-threatening diseases, indicating opportunities for related investments.
The insights into ACLY's role in diseases suggest potential new therapies, impacting biotech stocks and market sentiment around related pharmaceutical developments.
Esperion (NASDAQ: ESPR) has appointed Robert E. as a veteran industry executive, bringing decades of financial and leadership experience to the company.
The appointment of a seasoned executive like Robert E. can signal positive changes in leadership, potentially improving company performance and investor confidence in Esperion.
Esperion will initiate two Phase III studies on bempedoic acid, both as a standalone treatment and with ezetimibe, targeting pediatric patients with familial hypercholesterolemia.
Esperion's phase III studies on bempedoic acid could expand its market potential and revenue streams, impacting stock performance and investor sentiment positively.
Esperion Therapeutics will hold its Q4 2024 earnings conference call on March 4, 2025, at 8:00 AM ET, featuring key executives and analysts from various financial firms.
The earnings call provides insights into Esperion's financial performance and strategic direction, influencing stock valuation and investor sentiment. Key analysts' participation signals market interest.
FY24 total revenue increased 186% year-over-year to $332.3 million, with U.S. net product revenue rising 48% year-over-year to $115.7 million.
Significant revenue growth signals strong business performance and market demand, potentially leading to increased investor confidence and stock valuation.
Esperion Therapeutics (ESPR) reported a quarterly loss of $0.10 per share, better than the expected loss of $0.14, and improved from a loss of $0.50 per share a year prior.
Esperion's smaller quarterly loss than expected and a significant year-over-year improvement may indicate better operational efficiency, potentially boosting investor confidence and stock performance.
Frequently Asked Questions About ESPR Stock
What is Esperion Therapeutics Inc.'s (ESPR) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Esperion Therapeutics Inc. (ESPR) has a median price target of $5.00. The highest price target is $16.00 and the lowest is $2.05.
Is ESPR stock a good investment in 2025?
According to current analyst ratings, ESPR has 6 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $0.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ESPR stock?
Wall Street analysts predict ESPR stock could reach $5.00 in the next 12 months. This represents a 426.3% increase from the current price of $0.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Esperion Therapeutics Inc.'s business model?
Esperion Therapeutics generates revenue by developing and commercializing oral medications for cholesterol management, specifically targeting patients with cardiovascular disease who cannot achieve desired cholesterol levels with existing treatments. The company's lead product, a non-statin therapy, offers an alternative for statin-intolerant patients, thereby expanding the market for lipid-lowering therapies.
What is the highest forecasted price for ESPR Esperion Therapeutics Inc.?
The highest price target for ESPR is $16.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 1,584.2% increase from the current price of $0.95.
What is the lowest forecasted price for ESPR Esperion Therapeutics Inc.?
The lowest price target for ESPR is $2.05 from at , which represents a 115.8% increase from the current price of $0.95.
What is the overall ESPR consensus from analysts for Esperion Therapeutics Inc.?
The overall analyst consensus for ESPR is bullish. Out of 20 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $5.00.
How accurate are ESPR stock price projections?
Stock price projections, including those for Esperion Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.